Telix Pharmaceuticals Limited (NASDAQ:TLX) agreed on September 21 to acquire ITM Isotope Technologies Munich SE. The deal is worth up to $2.35 billion. Telix will pay $1.65 billion upfront, before cash and debt.
A further $700 million follows if ITM's lead drug wins approval and hits sales targets. Telix is paying mostly in its own stock, which is why the cost lands on shareholders now. It will issue 105.8 million shares, with the balance made up of ITM debt it assumes, transaction costs, and rolled-over management equity.
The deal needs approval from Telix shareholders and regulators, and should close by the end of the year. Radiopharmaceuticals treat cancer by delivering radiation directly to tumours. They only work if the radioactive isotope arrives in time, because the material decays within days.
ITM makes lutetium-177, one of the isotopes the field runs on. Telix says it is also the main outside supplier of that isotope to Pluvicto, the Novartis drug competing with what Telix is building. For Telix, isotope supply has mattered as much as trial results, because a delayed shipment ruins a dose that good data cannot rescue.
Telix has been buying its isotopes from outside suppliers, ITM among them, and after this deal it makes them itself. That removes a supplier margin and a scheduling risk. It also puts Telix on the other side of a competitor's supply, which is the part regulators will examine.
The deal also buys a drug that beat its trial endpoint but has not cleared the FDA. ITM-11 extended progression-free survival to 23.9 months in gastroenteropancreatic neuroendocrine tumours, well beyond the comparator. The only approved radiopharmaceutical rival is Novartis's Lutathera.
Extract — continue reading at the source.
